HOME >> BIOLOGY >> NEWS
Soliris (eculizumab) data to be presented at American Society of Hematology

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that abstracts relating to Soliris (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) have been published by the American Society of Hematology (ASH). Each of these abstracts will be presented at the 2006 ASH Annual Meeting in Orlando, Florida, December 9th to 12th by leading investigators in the Soliris (eculizumab) PNH clinical studies. Copies of the abstracts are available and can be viewed on-line through the ASH website: www.hematology.org/meetings/abstracts.cfm. Access to the on-line abstracts may require registration, for which there is no charge.

The following abstracts will be presented in oral sessions:

  • "The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria"
    Dr. Peter Hillmen et al.
    Time: Sunday, December 10th at 5:00pm
    Room 315
  • "Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III TRIUMPH Study Results"
    Dr. Jrg Schubert et al.
    Time: Sunday, December 10th at 5:15pm
    Room 315

The following abstracts will be presented in poster sessions:

  • "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study"
    Poster # 99-I
    Dr. Neal S. Young et al.
    Time: Saturday, December 9th at 9:00am
    Hall E-1
  • "Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization"
    Poster #100-I
    Dr. Anita Hill et
    '"/>


Contact: Tony Russo
tony.russo@eurorscg.com
212-845-4251
Euro RSCG Life NRP
8-Dec-2006


Page: 1 2

Related biology news :

1. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
2. Data presented at ISHLT meeting confirm RNA analysis can identify rejection in lung transplant recip
3. Latest plant health research to be presented in San Diego
4. Presidential Recognition Awards presented at the 2007 AIUM Annual Convention
5. Agronomy, crop, soils research presented in Indianapolis
6. UW-Madison work on stem cells, cardiac health to be presented at ACS
7. Weizmann Women & Science Award presented to Dr. Mary-Claire King
8. IOF-Novartis Young Scholars Awards presented to seven researchers from six countries
9. Coma misrepresented in movies
10. Latest plant disease research to be presented in Quebec City
11. AIUM Presidential Recognition Awards presented

Post Your Comments:
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... has different effects on different species of fish, ... of Bristol and Exeter which tested fish anti-predator ... a flying seagull predator model when exposed to ... European minnows. , Lead author Dr Irene ... "Noise levels in many aquatic environments have increased ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
(Date:7/24/2014)... 2014 Three companies from the angelMD ... Big C Competition. Out of 700 competition entrants, Chiron ... the semi-final round. In this round twenty teams are ... complete with mentoring from thought-leaders and medical entrepreneurs from ... the angelMD commitment to the Livestrong vision around the ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2
Cached News: